You are here : HOME / NETWORK / Mariona Graupera

Mariona Graupera

Supervisor

Institut de Recerca contra la Leucèmia Josep Carreras, Spain

Mariona Graupera is a group leader at the Josep Carreras Leukaemia Research Institute.

She obtained her PhD in Biochemistry from the University of Barcelona, focusing on the pathobiology of endothelial cells in liver cirrhosis. She carried out postdoctoral studies with Bart Vanhaesebroeck first at the Ludwig Institute for Cancer Research and later the Barts Institute of Cancer, London where she was involved in characterizing the physiological role of class I PI3K isoforms. In particular, Mariona Graupera unravelled the importance of being selective in angiogenesis during development. In 2009 she had the opportunity to create a multidisciplinary laboratory devoted to study PI3K/PTEN signalling in physiopathological angiogenesis at IDIBELL with a Ramon y Cajal position. In February 2021 Mariona Graupera was appointed the Group Leader of the Endothelial Pathobiology and Microenvironment Group to the Josep Carreras Leukaemia Research Institute where she combines her passion for biomedical research and vascular biology with the training of students and postdocs. Her group investigates the role of blood vessels in disease towards the development of therapeutic strategies to target the vascular compartment.

Supervisors

 Louis Maes (ESR13)

Publications

  • Phosphoinositide 3-Kinase-Regulated Pericyte Maturation Governs Vascular Remodeling.
    Figueiredo AM, Villacampa P, Diéguez-Hurtado R, José Lozano J, Kobialka P, Cortazar AR, Martinez-Romero A, Angulo-Urarte A, Franco CA, Claret M, Aransay AM, Adams RH, Carracedo A, Graupera M. Circulation. 2020 Aug 18;142(7):688-704.
  • Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
    Martinez-Corral I, Zhang Y, Petkova M, Ortsäter H, Sjöberg S, Castillo SD, Brouillard P, Libbrecht L, Saur D, Graupera M, Alitalo K, Boon L, Vikkula M, Mäkinen T. Nat Commun. 2020 Jun 8;11(1):2869. 
  • Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer.
    Hermanova I, Zúñiga-García P, Caro-Maldonado A, Fernandez-Ruiz S, Salvador F, Martín-Martín N, Zabala-Letona A, Nuñez-Olle M, Torrano V, Camacho L, Lizcano JM, Talamillo A, Carreira S, Gurel B, Cortazar AR, Guiu M, López JI, Martinez-Romero A, Astobiza I, Valcarcel-Jimenez L, Lorente M, Arruabarrena-Aristorena A, Velasco G, Gomez-Muñoz A, Suárez-Cabrera C, Lodewijk I, Flores JM, Sutherland JD, Barrio R, de Bono JS, Paramio JM, Trka J, Graupera M, Gomis RR, Carracedo A. J Exp Med. 2020 Jun 1;217(6):e20191787. 
  • PIK3CA mutations in vascular malformations
    Castillo SD, Baselga E, Graupera M. Curr Opin Hematol. 2019 May;26(3):170-178. 
  • Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility.
    Angulo-Urarte A, Casado P, Castillo SD, Kobialka P, Kotini MP, Figueiredo AM, Castel P, Rajeeve V, Milà-Guasch M, Millan J, Wiesner C, Serra H, Muixi L, Casanovas O, Viñals F, Affolter M, Gerhardt H, Huveneers S, Belting HG, Cutillas PR, Graupera M. Nat Commun. 2018 Nov 16;9(1):4826.
  • Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
    Berenjeno IM, Piñeiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, Morelli D, Kanu N, Srinivas S, Graupera M, Parker VER, Montgomery KG, Moniz LS, Scudamore CL, Phillips WA, Semple RK, Clarke A, Swanton C, Vanhaesebroeck B. Nat Commun. 2017 Nov 24;8(1):1773.
  • Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
    Okkenhaug K, Graupera M, Vanhaesebroeck B. Cancer Discov. 2016. 6(10):1090-1105. 
  • Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans
    Sandra D Castillo, Elena Tzouanacou, May Zaw-Thin, Inma M Berenjeno, Victoria E R Parker, Iñigo Chivite, Maria Milà-Guasch, Wayne Pearce, Isabelle Solomon, Ana Angulo-Urarte, Ana M Figueiredo, Robert E Dewhurst, Rachel G Knox, Graeme R Clark , Cheryl L Scudamore, Adam Badar, Tammy L Kalber, Julie Foster, Daniel J Stuckey, Anna L David , Wayne A Phillips, Mark F Lythgoe, Valerie Wilson, Robert K Semple, Neil J Sebire, Veronica A Kinsler, Mariona Graupera, Bart Vanhaesebroeck Sci Transl Med. 2016 Mar 30;8(332):332ra43.
  • PTEN mediates Notch-dependent stalk cell arrest in angiogenesis
    Serra H, Chivite I, Angulo-Urarte A, Soler A, Sutherland JD, Arruabarrena-Aristorena A, Ragab A, Lim R, Malumbres M, Fruttiger M, Potente M, Serrano M, Fabra À, Viñals F, Casanovas O, Pandolfi PP, Bigas A, Carracedo A, Gerhardt H, Graupera M. Nat Commun. 2015 Jul 31;6:7935.
  • Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
    Soler A, Serra H, Pearce W, Angulo A, Guillermet-Guibert J, Friedman LS, Viñals F, Gerhardt H, Casanovas O, Graupera M, Vanhaesebroeck B. J Exp Med. 2013 Sep 23;210(10):1937-45.
  • The emerging mechanisms of isoform-specific PI3K signalling
    Bart Vanhaesebroeck, Julie Guillermet-Guibert, Mariona Graupera, Benoit Bilanges. Nat Rev Mol Cell Biol. 2010 May;11(5):329-41.
  • Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.
    Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B. Nature. 2008 May 29;453(7195):662-6. 

    • Questions about PIPgen?

    Let’s talk!

    PIPgen coordinator

    Josep Carreras Leukaemia Research Institute
    Ctra de Can Ruti, Camí de les Escoles, s/n
    08916 Badalona, Spain

    PIPgen@carrerasresearch.org

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 955534

    Nicoline Hoogerbrugge Klaus Okkenhaug